Banyan Biomarkers, Abbott Ink Deal for Traumatic Brain Injury Biomarkers
UF startup and UF Innovate | Sid Martin Biotech alum Banyan Biomarkers announced that it has nonexclusively licensed its proprietary blood biomarkers of traumatic brain injury (TBI) to Abbott.
The biomarkers — ubiquitin carboxyl-terminal hydrolase-L1 and glial fibrillary acidic protein — can be detected in blood soon after a brain injury. They are the basis of San Diego-based Banyan’s Brain Trauma Indicator, which received marketing authorization from the US Food and
Drug Administration in early 2018.